Genmab

	14/7 09:30 af Helge Larsen/PI-redaktør	Super. :-D
	14/7 09:20 af E L	-end-
	14/7 09:20 af E L	future where forthcoming clinical trials use the subcutaneous formulation rather than traditional daraIV. For these reasons, and assuming FDA/EHA approval in the near future, we support the use of dara-SC for both standard of care and investigational use moving forward.
	14/7 09:20 af E L	If ongoing trials show activity in these respective indications the use of the drug will only grow, further stressing health care resources in many areas. Additionally, limiting cancer patients’ time in busy infusion clinics will decrease their potential exposure to current and future pathogens of which they are inherently vulnerable, and at risk for more serious complications if infected. It would be reasonable to envision a
	14/7 09:20 af E L	It is not surprising that daratumumab is currently under evaluation in both other hematologic malignancies (acute lymphoblastic lymphoma, acute myeloid leukemia, non-Hodgkin lymphoma), as well as bladder and renal cell carcinoma previously treated with PD-1/PD-L1 antibodies.
	14/7 09:18 af E L	" One can certainly imagine a case where a patient is given a clinically inferior regimen due to these logistical issues. The development of the subcutaneous formulation of daratumumab reviewed in this paper allows for rapid administration with a significantly diminished risk for daratumumab-related IRRs, potentially allowing expanded access to a powerful anti-myeloma therapy in areas where healthcare resources may be limited"
	14/7 09:18 af E L	"As daratumumab continues to accumulate approvals in more front-line combinations its use is only expected to increase. Unfortunately, the labor intensive, protracted initial infusions and significant risk of IRRs have potentially limited its utility in areas with limited healthcare resources. Indeed, in many areas a patient may need to get their initial 1-2 infusions at a tertiary care facility, with subsequent administrations provided in the community setting."
	14/7 09:15 af Helge Larsen/PI-redaktør	Pharma og biotek under pres som så meget andet her i åbningen.
	14/7 09:14 af E L	"Additionally, the decreased infusion time should translate to improved quality of life, less healthcare resource use, and increased economic benefit in terms of decreased time away from work and increased productivity."
	14/7 09:14 af Helge Larsen/PI-redaktør	Ok. :-)
	14/7 09:02 af Bulder	It's because it's sci-hub. No access from Denmark.
	14/7 09:01 af Helge Larsen/PI-redaktør	The link to the full article do not function for me.
	14/7 08:57 af Helge Larsen/PI-redaktør	Expert opinion " Subcutaneous daratumumab is non-inferior to conventional intravenous daratumumab with lower risk of infusion-related reactions and decreased administration time. Based on these data, and the recent FDA and European Commission approvalsthe widespread use of the subcutaneous formulation for both conventional and investigational practice is supported".
	14/7 08:57 af Helge Larsen/PI-redaktør	Thanks E L. :-)
	14/7 08:54 af E L	full article (link) i suggest reading at least the conclusion and expert opinion
	14/7 08:54 af E L	An evaluation of subcutaneous daratumumab for the treatment of multiple myeloma (link)
	14/7 06:38 af Helge Larsen/PI-redaktør	Foreløbigt er det en nødløsning til vi får råd til en bedre teknisk løsning.
	14/7 06:37 af Helge Larsen/PI-redaktør	Pensionist...Det er i kronogisk orden, men er svært at læse. Det bliver bedre. Det er foreløbigt blot en test. Det er meningen at der kun bliver slået en dag ad gangen op. Det er mere overskueligt.
	14/7 06:34 af Helge Larsen/PI-redaktør	God morgen. :-)
	13/7 22:55 af Helge Larsen/PI-redaktør	Servicemeddelse: Jeg har lavet to chats til Finans- og Økonomikalendere. Jeg opdaterer disse løbende frem over.
	13/7 17:08 af gdn55	Nå, det gik jo ikke så galt idag alligevel.
	13/7 16:20 af E L	another PET/CT Scan trial With the Radioactive Tracer 89Zr-DFO-Daratumumab (link)
	13/7 16:06 af Mcjean	Søg job på Jyllandsposten, din analyse er klart skarpere end deres!
	13/7 14:19 af E L	;)

	13/7 13:53 af Solsen	Thanks I see JW is still CEO ;-)
	13/7 13:34 af E L	(link)
	13/7 11:29 af E L	DnB Markets Rune Majlund Dahl Genmab (Hold, TP: DKK2400.00) - Limited Covid-19 impact We expect slightly lower Darzalex sales in Q2 QOQ due to Covid-19, and estimate global sales of USD936m. We are at the mid-point of the USD3.9bn–4.2bn sales guidance for 2020e.
	13/7 11:25 af GeorgeBest	Nogen estimater på Q2 salgstal torsdag? Jeg lægger ud gæt med USD 980M!
	13/7 10:17 af E L	Lancet - Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial (link)
	13/7 09:10 af Vitus	Det kan nu godt se ud som om der er noget om snakken !!
	13/7 09:09 af Helge Larsen/PI-redaktør	Må dog konstatere at Novo, GEN, ZEAL, BAVA og AMBU falder i åbningen. Så mange kan der da ikke være som læser Jyllandspostens finansside. ;-)
	13/7 09:07 af Helge Larsen/PI-redaktør	Fred være med det. :-)
	13/7 08:53 af Helge Larsen/PI-redaktør	Er det ikke det samme link som jeg lagde i går aftes kl. 20.12. (link)
	13/7 08:00 af Mogan	God morgen :-)
	13/7 07:18 af transalp	Go morgen.. :)
	12/7 20:12 af Helge Larsen/PI-redaktør	Helge Larsen har delt et link. Administrator · 1 min · Delt med Medlemmer af PROINVESTORS PHARMA - OG BIOTEK SNAK Fred være med lidt modvind. De danske sundhedsaktier strutter fundamentalt af sundhed. Det gør de også på den lange bane.(link)
	12/7 12:39 af E L	full pdf (link)
	12/7 12:39 af E L	Daratumumab for disabling cold agglutinin disease refractory to B‐cell directed therapy (link)
	12/7 08:15 af Helge Larsen/PI-redaktør	God morgen. :-)
	12/7 06:58 af bibob	JvdW bliver rådgiver for hollandsk venturafond. (link)
	12/7 06:57 af bibob	God morgen. :-).
	11/7 16:52 af henrik48	Du er utrættelig Helge...god weekend
	11/7 12:40 af Helge Larsen/PI-redaktør	Jeg har opdateret vores Genmab-gruppe på Facebook med hensyn til navn og coverbillede. (link)
	11/7 08:32 af Helge Larsen/PI-redaktør	God morgen. :-)
	10/7 23:57 af Helge Larsen/PI-redaktør	Servicemeddelelse. Der kan forekomme enkelte udfald på websiden i nat og i løbet af weekenden. Vi arbejder med ændringer og opdateringer. God weekend til alle. :-)
	10/7 21:00 af Budweis	Genmab locates U.S. headquarters in Princeton
	10/7 21:00 af Budweis	(link)
	10/7 17:04 af Helge Larsen/PI-redaktør	Det må man sige. Også god weekend til dig, :-)
	10/7 17:01 af Helge Larsen/PI-redaktør	25.000 handlet i auktionen. Det var det samme antal som blev dumpet i går i det døende minut.
	10/7 16:58 af Stroka	I lige måde Aab. :-)